Disease Landscape and Forecast Insights
Comprehensive market intelligence and actionable insights help you optimize your long-term disease strategy
Dry and Wet Age-Related Macular Degeneration – Access & Reimbursement – Access & Reimbursement – Age-Related Macular Degeneration (US)
The age-related macular degeneration (AMD) therapy market in the United States is unique because the market penetration of approved branded therapies—Roche / Genentech’s Lucentis, Regeneron’s…
Rheumatoid Arthritis – Access & Reimbursement – Access and Reimbursement – Rheumatoid Arthritis (US)
The availability of multiple targeted therapies with diverse mechanisms of action, including biologics / biosimilars and oral agents, along with conventional treatments, makes the rheumatoid…
Ulcerative Colitis – Access & Reimbursement – Access & Reimbursement – Impacts of Biosimilar Adalimumab Launches in Autoimmune Disease (US)
2023 marks a pivotal year for the autoimmune space as numerous releases of biosimilar adalimumab challenge the market dominance of AbbVie’s Humira, one of the best-selling brands in the United…
Dry and Wet Age-Related Macular Degeneration – Geographic Focus: China – Dry and Wet Age-Related Macular Degeneration – China In-Depth (China)
Age-related macular degeneration (AMD), which includes dry and wet AMD, is a leading cause of irreparable vision loss globally. In China, patients with wet AMD are typically treated with VEGF…
Rheumatoid Arthritis – Geographic Focus: China – Rheumatoid Arthritis – China In-Depth (China)
Rheumatoid arthritis (RA) is a chronic and progressive autoimmune disease that primarily affects the joints. China has the highest number of RA patients in the world, and disease management is…
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia | China In-Depth | China | 2022
Of the four subtypes of non-Hodgkin’s lymphoma (NHL), diffuse large B-cell lymphoma (DLBCL) is the most common in China. Rituximab (Roche’s MabThera, biosimilars) continues to dominate China’…
